Cenegermin-Bkbj

DRUG3 trials

Sponsors

Dompé Farmaceutici S.p.A, Stanford University, Tufts Medical Center

Conditions

Corneal DiseaseNeuropathyNeurotrophic Keratitis

Phase 1

NGF Treatment for Patients With Neuropathic Corneal Pain

WithdrawnNCT05700864

Tufts Medical CenterCorneal Disease, Neuropathy

Start: 2022-11-01End: 2023-12-01Updated: 2023-01-26

Phase 4

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

CompletedNCT04485546

Dompé Farmaceutici S.p.ANeurotrophic Keratitis

Start: 2020-09-09End: 2022-03-30Updated: 2025-11-17

Unknown Phase

Nerve Growth Factor for the Treatment of Cornea Disease

CompletedNCT04552730

Stanford UniversityNeurotrophic Keratitis

Start: 2020-10-14End: 2021-05-04Updated: 2021-12-14

Related Papers

Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).

2024-01-049 citations

Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy

Therapeutic Advances in Ophthalmology2022-01-016 citations